Analysis updated on Nov. 3, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Our AI scores Cytodyn Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Cytodyn Inc. is a small-cap company with a market capitalization of $323M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Current Ratio of 0.38x is the lowest of the 58 peers that report one.
For CYDY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CYDY included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | CYDY | Rank |
|---|---|---|
| Market Cap | $323M | 60/60 |
| EPS | $-0.04 | – |
| Metric | CYDY | Rank |
|---|---|---|
| ROA | -272.5% | 43/43 |
| ROIC | 128.9% | 2/44 |
| Tax Rate | 0.0% | – |
| Metric | CYDY | Rank |
|---|---|---|
| Current Ratio | 0.38x | 58/58 |
| Interest Coverage | -315.1x | 31/34 |
| Working Capital | -$31M | 52/58 |
| Metric | CYDY | Rank |
|---|---|---|
| Operating Cash Flow | -$20M | 39/59 |
| Metric | CYDY | Rank |
|---|---|---|
| Operating Income | -$40M | 29/51 |
| Net Income | -$52M | 28/48 |
| Metric | CYDY | Rank |
|---|---|---|
| Shares Outstanding | 1470M | – |
| Total Current Assets | $19M | |
| Cash & Short-term Investments | $16M | |
| Total Liabilities | $117M | |
| Short-term Debt | $37M |
Companies classified under the same SEC industry code as Cytodyn Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CYDY Cytodyn Inc. | $323M | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $651.32B | |
| ABBV Abbvie Inc. | $521.11B | |
| MRK Merck & Co., Inc. | $366.03B | |
| NVS Novartis Ag | $308.20B | |
| AZN Astrazeneca Plc | $285.01B | |
| ABT Abbott Laboratories | $190.23B | |
| NVO Novo Nordisk A S | $177.76B | |
| PFE Pfizer Inc | $174.81B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $136.87B | |
| BMY Bristol Myers Squibb Co | $126.14B | |
| SNY Sanofi | $106.33B | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.97B | |
| GSK Gsk Plc | $98.25B | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | |
| TEVA Teva Pharmaceutical Industries Ltd | $47.43B | |
| ONC Beone Medicines Ltd. | $41.07B | |
| GMAB Genmab A/S | $36.34B | |
| ZTS Zoetis Inc. | $34.37B | |
| RPRX Royalty Pharma Plc | $28.77B | |
| ROIV Roivant Sciences Ltd. | $25.92B | |
| UTHR United Therapeutics Corp | $25.57B | |
| INSM Insmed Inc | $22.91B | |
| VTRS Viatris Inc | $21.44B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.42B | |
| ASND Ascendis Pharma A/S | $16.43B | |
| BBIO Bridgebio Pharma, Inc. | $14.42B | |
| JAZZ Jazz Pharmaceuticals Plc | $13.92B | |
| ELAN Elanco Animal Health Inc | $12.28B | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | |
| SMMT Summit Therapeutics Inc. | $11.81B | |
| BMRN Biomarin Pharmaceutical Inc | $10.77B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.96B | |
| TGTX Tg Therapeutics, Inc. | $9.22B | |
| PTGX Protagonist Therapeutics, Inc | $9.02B | |
| CORT Corcept Therapeutics Inc | $8.86B | |
| CYTK Cytokinetics Inc | $8.66B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | |
| SYRE Spyre Therapeutics, Inc. | $8.42B | |
| ALKS Alkermes Plc. | $7.67B | |
| PRAX Praxis Precision Medicines, Inc. | $7.65B | |
| AXSM Axsome Therapeutics, Inc. | $7.31B | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.09B | |
| ABVX Abivax S.A. | $6.97B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.45B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | |
| ORKA Oruka Therapeutics, Inc. | $6.32B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| BLTE Belite Bio, Inc | $5.99B | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | |
| MANE Veradermics, Inc | $5.41B | |
| COGT Cogent Biosciences, Inc. | $5.39B | |
| ERAS Erasca, Inc. | $5.12B | |
| PTCT Ptc Therapeutics, Inc. | $5.08B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.63B | |
| TVTX Travere Therapeutics, Inc. | $4.41B | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | |
| EWTX Edgewise Therapeutics, Inc. | $4.09B |
CytoDyn Inc.’s investor agreement to shell out 49 million shares and $500,000 in cash earned final court approval, ending allegations that it misrepresented progress on regulatory approvals for a ...
Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ...
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in ...
Our AI scores Cytodyn Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For CYDY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -36.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Cytodyn Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
60 issuers in our coverage, CYDY included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
